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Allergen specific immunotherapy (AIT) has been the only pathogenetically relevant treatment of IgE-mediated allergic
diseases (ADs) for many years. The use of AIT for atopic dermatitis (AD) treatment is dubious and has both followers
and opponents. The improvement of subcutaneous AIT (SCIT) and introduction of Sublingual immunotherapy (SLIT)
gives prospects of their application both for adults and children suffering from AD. This review presents results of
scientific research, system and meta-analyses that confirm the clinical efficacy of AIT for children with AD who has the
sensitization to allergens of house dust mite, grass and plant pollen suffering from co-occurring respiratory ADs and
with moderate and severe course of allergic AD. There have been analyzed the most advanced achievements in AIT
studies as well as there have been specified the unmet needs in AD. The preliminary diagnostics of IgE-mediated AD
and pathophysiological disorders, including immune ones, will allow a doctor to develop appropriate comprehensive
treatment algorithm for children’s AD aimed at its correction. The including of AIT to the children’s comprehensive
therapy program is reasonable only if AD has the allergic form. It is necessary better to design the randomized research
studies and to acquire extended clinical practice in children with AD. Use of the successes of molecular-based allergy
diagnostics will help to optimize and personalize the process of selecting the necessary allergens to determine the
most appropriate vaccines for children considering the results of the allergen component diagnostics. The strategy of
treatment of children with AD in future will be based on individual target therapy.
Keywords: Allergen specific immunotherapy, Subcutaneous specific immunotherapy, Sublingual specific immunotherapy,
Aeroallergen, Atopic dermatitis, Children, Clinical efficacyBackground
Atopic dermatitis (AD)—is a chronic inflammatory aller-
gic disease (ADs) of the skin with multifactorial pathogen-
esis. Its development proceeds against the background of
various and interdependent genetical, ecological, immuno-
logical, psychological, biochemical and other pathological
processes, the most important of which is dysfunction of
skin barrier [28, 44, 50, 79, 84, 96]. The skin barrier
protective dysfunction causes the acceleration of second-
ary infection overlay and extraneous antigens penetration
through damaged corneal layer. The prevalence of adults’* Correspondence: slavyanskaya_ta@pfur.ru
Tatiana Slavyanskaya is the first author.
1People’s Friendship University of Russia, Moscow, Moscow region, Russia
2Institute of Immunophysiology, Moscow, Russia
Full list of author information is available at the end of the article
© 2016 Slavyanakaya et al. Open Access This
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeand children’s AD is steadily increasing all over the world
and now reaches over 1–20 % (approximately 20 % for
children and 1–3 % for adults) [28, 58, 72, 85].
For the last twenty years in many countries there
have been fixed the increase of prevalence of the dis-
ease [29, 67, 86], as well as the increase of severe and
complicated AD incidence with permanently relapsing
course that is resistant to basic traditional therapy (BT)
[10, 59, 77, 78, 80]. According to the references infec-
tious complications occur in 25–34 % of children suf-
fering from AD [8, 41, 90, 95]. Acquiring the chronic
course with frequent recurrence the disease keeps its
clinical features for many years. The Severe AD sharply
reduces the patient’s and his family’s quality of life
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later in 40–50 % of children suffering AD. Subsequently,
40–50 % of children suffering from AD, have BA, food
allergy, pollen allergy and/or AR evolved.
Atopic dermatitis and allergens
Ethiopathogenetic reasons for AD are still the subject of
wide discussion. Most of the authors mark the critical
pathogenetic role of IgE-mediated mechanisms of hyper-
sensitivity in relation to many foods, domestic and/or
environmental allergens. The Immunologic Triggers of
AD are Foods, Aeroallegens, Staphylococcus aureus,
Viral Infection, Autoallegens, Fungi. Many patients with
AD are sensitized to seasonal and perennial aeroaller-
gens, which can play a key role in activation or retention
of the skin disease occurrence. However, it is rather
problematic to obviate the pollen allergens—aeroaller-
gens (house dust mite, grass and plant pollen).
Among the most important etiological factors in AD de-
velopment are allergens of house dust mites and their waste
products (HDMA). At the moment, there have been distin-
guished 24 HDMA, representing the families: Pyroglyphi-
dae mainly Dermatophagoides pteronyssinus, D. farinae,
and Euroglyphus maynei), Glycyphagidae (e.g. Lepidogly-
phus destructor, Blomia sp.) and Acaridae (e.g. Tyrophagus
putrescentiae, Acarus siro) [42, 88, 89]. These allergens are
responsible for allergic reactions in diseases such as AR, BA
and AD. It is determined that approximately 5 % of people
are sensitive to house dust mite allergens (HDMA). Due to
high enzymatic activity HDMA are able to penetrate
through the damaged epidermal skin barrier of patients
with AD to get the access to immune cells. HDMA cause
allergic response both of immediate and delayed types that
leads to worsening of AD [13]. Double-blind controlled re-
search has proved the HDMA role in children and adults’
AD initiation [40, 87].
Gutgesell et al. [40] conducted a randomized research in
studying the HDMA role in the initiation of AD and
weighting its clinical manifestations, which included 20
adult patients with moderate and severe forms of AD. In
the group of patients with active treatment, special mea-
sures were conducted preventing the penetration of
HDMA, but the control group did not receive it. The sever-
ity of the disease was judged every 2 months throughout
the year according to the established SCORAD system,
eosinophil cationic protein (ECP) in serum in ELISA and
quantitative use of topical steroids. In addition, weekly on a
visual analogue scale the patients themselves rated daily
itching and itching, inducing insomnia. Some of the pa-
tients in the active treatment group reported the reduction
of itching, inducing insomnia, however, the statistically sig-
nificant differences between the groups were not revealed.
In adult patients with AD it has been shown that the reduc-
tion of the HDMA impact during the year improves someclinical symptoms of the disease, but does not influence on
the activity of the disease. This research has confirmed the
important role of HDMA in the development and mainten-
ance of the AD symptoms. At the same time HDMA and
other aeroallergens are successfully being used as potential
preventive and therapeutic variant for AIT in treatment of
patients with AD [5, 11, 13, 26, 27, 46, 54, 57, 60].
Deep insight of immunological disorders contributing
to the AD pathogenesis has caused the increase of inter-
est in applying of AIT according to this disease. AIT
applying in case of AD requires thorough discussion and
analysis of available clinical data to determine with cer-
tainty its positive or negative effect on the disease
course. AIT in case of AD is still a subject of debates
that take place in sessions of many scientific forums
where scientists and clinicians express their opinions,
discuss and provide evidences of the efficacy of this
method or argue to restrict its use.
Efficacy of Subcutaneous AIT in children with AD
Reports on AD treatment, particular in children, appear
regularly in world’s literature (Table 1). First encouraging
randomized studies on applying SCIT for treatment of
children and adults with AD were published in 1970s. In
1974, Kaufman и Roth [45] carried out the quasi-
randomized controlled study among 52 adults and chil-
dren with AD. In total only 26 patients completed the ex-
periment with SCIT that lasted for 2 years. In the process,
the significant improvement was noticed in 81 % of cases
in the SCIT group compared to 40 % in placebo group.
In 1978, Warner et al. [92] conducted the double blind
randomized placebo-controlled research of children with
BA and 20 children who additionally have signs of atopic
allergy. Upon the 1 year of treatment with SCIT, in the
patients’ and their parents’ opinion, there was noticed
the subjective improvement of eczema in active treat-
ment group (77.8 %), compared to minimal improve-
ment in placebo group (27.3 %).
In 1980–90s results of double blind placebo-controlled
studies were published where Ring [71] and Glover et al.
[43], showed the efficacy of SCIT applying for AD
treatment.
Thus, the experiment was carried out on treatment of
identical twins suffering from atopic eczema (with spring
and summer exacerbations), one of whom got SCIT with
grass pollen allergens and another—got placebo. Patient
who got immunotherapy showed significant improve-
ment of clinical features and reduction of serum IgE
levels (Ring [82]).
Glover et al. [39] in their research of applying SCIT
with HDMA in treatment of 24 children with AD re-
vealed the statistically significant change of clinical effi-
cacy in comparison with placebo only if it had been
applied for more than one year. That demonstrated the
Table 1 Clinical studies of SCIT/SLIT efficacy in AD
Authors Year of
research
Country Study
design
The number of patients
(treatment/control)
Category of the
patients (Age)
The type of allergen Route of
administration
The total duration
of the study
(in months)
Clinical efficacy (the opinion
of the Clinician -C/patient-P)
Treatment/control (in %)
Reference
number
Kaufman H.S.,
Roth H.L.
1974 US qRCT DB
PC
52 (26/26) children/adults
(2–47)
animal dander,
HDM molds, pollen
SCIT 24 C(+) 45
81,3/40
Warner J.O. et al. 1978 UK RCT DB PC 20 (9/11) children (5–14) HDM SCIT 12 P(+) 92
77,8/27,3
Ring J. 1982 Germany RCT DB PC 2 (1/1) children (10) Grass pollen SCIT 24 C(+) 71
SCORAD improvement
from score 30→10/26→21
Glover M.T.,
Atherton D.J.
1992 UK RCT DB PC 24 (13/11) children (5–16) HDM SCIT 8 -13,5 P(+) 39
61,5/81,8
Galli E. et al. 1994 Italy RCT DB PC 60 (NM) children (0,5-12) HDM SCIT Till 36 (mean
duration 18.7)
C(+) 38
Group A (AD+AR/BA)/Group
B&Group C (AD) Improvement
of skin lesions: 81/63/61
Silny M., Czarnecka-
Operacz W.
2006 Poland RCT DB PC 20 (10/10) children/adults
(5–40)
dander, HDM pollen
(adsorbed with
aluminum hydroxide)
SCIT 12 C(+) 76
80/10 on the base of W-АЗС
index, specific IgE (р<0,001)
Silny W. et al. 2005 Poland CT 68 (36- HDM+ 12-
Pollen/20-BT***)
children/
teenagers
HDM Pollen SCIT 36 C(+) 73-75
Significant clinical efficacy
W-АЗС index > BT (р <0,001)
Czarnecka-
Operacz M,
Silny W.
2006 Poland NM 66 NM (subgroup
with different
age)
HDM/grass pollen/
grass + mugwort
pollen
SCIT 48 C(+) 25
Significant clinical efficacy with
IgE-mediated airborne allergy
37(14/17/6)/29
Bussmann C. et al. 2006
(2007)
Germany pilot study
(systematic
overview)
25 NM HDM SCIT 4 C(+) 13,14
SCORAD, specific IgE, IgG4, IL-10
Slavyanskaya T. et al., 2013-
2015
Russia CT 350 children/
teenagers
(3–18)
HDM SCIT ≥36 C(+) 29-35,
77,78,
80-83Derkach V. et al. 300/50 (moderate-
severe AD)
QOL (scores) 11.32→ in 3 times
decreased (р<0,001), SCORAD
42,57→5,19, specific IgE, IL-4,
IL-10
Note: SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, AD atopic dermatitis, AR allergic rhinitis, BA allergic bronchial asthma, HDM house-dust mite, qRCT quasi-randomized controlled trial, RCT DB
PC randomized controlled trial double-blind placebo-controlled, CT clinical trial, NM not mentioned, SCORAD severity scoring of atopic dermatitis, QOL quality of life, C (+) presence, by clinician, P (+) presence, by
patient
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to reach the clinical effect.
In 2006 EAACI/AAAAI in joint document (PRAC-
TALL Consensus Report) [93], dedicated to AD diagnos-
tics and treatment brought into focus that further well-
controlled studies are required to determine future role
of immunotherapy for children and adults with AD.
And already in 2006 Silny et al. [76] presented their
study with the results of double blind placebo-controlled
research of patients with AD. For the SCIT efficacy esti-
mation in AD control, they used both clinical and
immunological criteria. During 12 months, 20 patients
aged between 5 and 40 years old with AD and
sensitization to HDMA or grass pollen allergens got
SCIT with medications of allergens adsorbed with
aluminum hydroxide. Clinical efficacy of treatment (the
extent and severity of patients’ with AD skin inflamma-
tion against itching and sleep disturbance) was assessed
by W-АЗС index. Immunological parameters included
the research of levels of general and specific IgE in the
blood serum, ECP, SIL-2R, IFN–γ, IL-4, IL-5 and IL-10.
It was shown that after 12 months of therapy there was
proven improvement of clinical features in the group of
patients who had got SCIT compared with placebo
group (р < 0.001). The level of serum specific IgE in the
SCIT group had a tendency to decrease, while in the pla-
cebo group it had a tendency to increase. The concen-
tration of serum immunological parameters including
ECP, SIL-2R, IFN-γ, IL-4, IL-5 and IL-10, which were
analyzed before and after treatment, didn’t show the sig-
nificant difference. Judging by the significant improve-
ment of clinical index and reliable decrease of specific
IgE level, SCIT turned out to be quite effective method
of IgE-mediated AD treatment.
Other series of studies (not blind, placebo-controlled)
was made by Silny et al. [73–75] on 36 children and teen-
agers with AD. 24 patients sensitive to HDMA and 12
patients sensitive to grass pollen allergens were given
SCIT with respective allergens for 3 years. The control
group included 20 AD patients with similar IgE-mediated
AD, who were given BT. The clinical efficacy of specific
immunotherapy based on the W-АЗС index was much
higher than that of BT (р <0.001). By the end of the treat-
ment course there was determined clear reliable difference
in the values of the studied immunological parameters be-
tween experimental and control group (concentration of
general and specific IgE, ECP, SIL-2R, IL-4, IL-5). SCIT
turned out to be effective in case of its long-time applying
to children with Ig-E-mediated AD.
Of note, conducting randomized research in children
is very difficult. However, over the last 20 years a lot of
isolated open pilot studies were made in this field. They
confirmed the clinical efficacy of SCIT with aeroaller-
gens (HDMA, grass, birch, sage pollen allergens) withlong-term (from 1 to 3 years) treatment of children and
adults with moderate and severe AD or AD developing
on the background of AR and BA, where SCIT was used
as an additional therapeutic approach to BT [13, 14, 23,
25–27, 49, 53, 55, 56, 72, 74, 91, 94]. Good results were
obtained in all studies that allowed the authors to
consider SCIT to be quite prospective method of skin
inflammation treatment and really effective and safe
alternative method of treatment for patients with AD
having IgE-mediated allergy to aeroallergens.
Our experience of using SCIT in children 5–18 years
old with moderate and severe AD and sensitization to
HDMA also has showed the positive results [29–31, 34,
35, 77, 78, 80, 82, 83]. In the plan of treatment, except
BT and SCIT, additionally was included immunomodula-
tor [31–33, 81, 82]. In the group of children with AD
who has used SCIT for 3 years minimum a significant
reduction of SCORAD-index was recorded as well as the
decreased number of exacerbations, the reduced amount
of BT without AD symptoms augmentation and in-
patient care. They have also showed the improvement of
their lives quality and long-term effect of treatment
(period of observation is over 5 years). Besides SCIT was
pharmaco-economic efficiency.
Efficacy of Sublingual AIT in children with AD
Sublingual immunotherapy (SLIT) was introduced as
safer variant of SCIT [12, 18–20, 22, 23, 63, 66] to solve
the problem of adverse reactions that are rare but pos-
sible with traditional SCIT. SLIT treatment is well toler-
ated, adverse reactions are local; mostly the reactions are
in mouth cavity or gastrointestinal tract. System reac-
tions related to skin, respiratory tract or anaphylaxis are
extremely rare [37]. SLIT is much safer than SCIT and
no evidences of anaphylaxis were registered after the in-
fusion to different patients with AD more than 500 mil-
lion doses. SLIT is significant step forward and is
particularly suitable for pediatric patients.
However, to assess the clinical effectiveness there was
made a number of clinical studies, including random-
ized, placebo-controlled. Despite the fact that number of
AD studies is not enough, however the results obtained
by the authors are promising (Table 2).
In 1994 Galli et al. [38] published first placebo-
controlled study with the use of oral allergen-specific ther-
apy in children with AD sensitive to HDMA. The study
involved 60 children who were divided into 3 groups: chil-
dren with AD and children with AD in combination with
BA/AR. A group of children with AD was divided into 2
parts: one of which was a control group and was given
placebo. Two other groups got active treatment. In total,
clinical studies were conducted during 3 years. And
thought the study did not reveal significant difference in
the clinical assessment of dermatological changes in the
Table 2 Summary characteristics of the clinical efficacy of SLIT in AD
Authors Year of
research
Country Study design The number of patients
(treatment/control)
Category of the
patients (Age)
The type
of allergen
Route of
administration
The total duration of
the study (in months)
Clinical efficacy (the opinion
of the Clinician -C/patient-P)
Treatment/control (in %)
Reference
number
Petrova S.I. et al. 2006 Russia RCT DB PC 99 (28-SLIT/39-
placebo/32-BT)
teenagers/adult HDM SLIT NM C(+) 68
Improvement in the
SLIT group
Pajno G.B. et al. 2007 Italy RCT DB PC 56 (28/28) children (5–16) HDM SLIT 18 C(+) 60
Improvement in
mild-moderate
forms after 9 months
of treatment. SCORAD
was significant (P = .025)
Di Rienzo V. et al. 2014 Italy Multicentric
RCT open,
parallel-group
study
NM children (5–18) HDM SLIT 18 C(+) 36
Effectively in children
with AD
Qin Y.E. et al. 2014 Chinese RCT DB PC 107 (58/49) NM HDM SLIT 12 C(+) 70
77.78/53.85 (P < 0.05)
Cadario G. et al. 2007 Italy pilot study 86 (53 females
and 33 males)
children/adults
(3–60)
HDM SLIT 12 C(+) 16
SCORAD Improvement
from score 43,3→23,7
Reduces the SCORAD
Note: SLIT sublingual immunotherapy, AD atopic dermatitis, AR allergic rhinitis, HDM house-dust mite, RCT DB PC randomized controlled trial double-blind placebo-controlled, CT clinical trial, NM not mentioned,
SCORAD severity scoring of atopic dermatitis, C (+) presence, by clinician
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with HDMA extracts occurs without any adverse reac-
tions and doesn’t affect the natural course of AD.
In 2007 Pajno G.B. et al. [60] conducted a double blind
randomized placebo-controlled study using SLIT with
HDMA in 56 children with AD between 5–16 years old
with SCORAD index > 7. 28 children took SLIT for
18 months in addition to standard therapy. It is import-
ant to note that in the group of children treated with
SLIT, SCORAD index began to decline abruptly after
9 months of treatment and need for drugs for the treat-
ment of AD in this group was reduced significantly com-
pared with placebo group. A positive result of this
therapy was noticed only in the patients with mild, mod-
erate AD, but not with severe form of AD. The authors
made a conclusion that SLIT can be an additional thera-
peutic tool for the treatment of allergic AD in properly
selected, for such method, children.
In an open, uncontrolled, non-randomized pilot study
Cadario et al. [16], conducted on 86 adults and children
aged 3–60 years with mild and moderate IgE-mediated
AD, studied the clinical efficacy (SCORAD) and safety of
SLIT with HDMA. The use within 12 months of SLIT
with HDMA extract in the patients with mild and mod-
erate AD was effective and well tolerated. After a year of
SLIT treatment decrease of SCORAD index was noted
and the gradual reduction of concomitant therapy with
actual corticosteroids or immunosuppressors.
Larenas-Linnemann [47] presented an analytical re-
view of the studies on the use of modified, modern vari-
ants of AIT – SLIT and oral AIT which are most
interesting for use in pediatric practice. Analysis of the
result of tests carried out on adults and children showed
that with a high degree of certainty it can be proven that
high doses of SLIT, in its daily conduct, reduce both
ADs symptoms and amount of drugs required for treat-
ment. Low doses of SLIT reduce the development of
new sensibilizations and in mild and moderate form of
AD course decrease the symptoms of the disease.
The Systematic review and meta-analysis of 8 studies
(6 – using SCIT and 2 with SLIT) on the AIT efficacy in
385 patients (adults and children) with AD sensitive
mainly to HDMA Bae et al. [9] revealed that the use of
aIT is justified in case of severe uncontrolled AD. In
general, despite the dichotomous results presented in the
studies, the meta-analysis provided moderate quality evi-
dence of AIT efficacy in AD. However, these conclusions
were based on analysis of a small number of randomized
controlled studies with significant heterogeneity in re-
search, which did not allow to make final conclusion
about the efficacy of AIT in AD.
Pleskovic N. et al. [69] when comparing SCIT and SLIT
in children showed similar clinical efficacy, but SLIT was
a safer therapy. SLIT is confidently recommended for usein pediatric practice for patients suffering from AR or
ARC for the environmental allergens. The use of SLIT as
an alternative treatment for pediatric patients with AD is
under development.
In 2014 Di Rienzo et al. [36] conducted a multicenter
randomized study on the use within 72 weeks of SLIT
with HDMA in children 5–18 years old with AD associ-
ated/not associated with allergic respiratory diseases and
came to the conclusion that immunotherapy was effi-
cient for children with AD.
Arkwright et al. [7] in their study showed an example
of SLIT treatment of 7 years old child with severe AD
and high concentration of IgE to HDMA. It was found
that SLIT didn’t lead to an improvement of AD course
but had a beneficial impact on the girl’s collateral AR.
Choi et al. [21] in their work has published the results of
using for 1 year SLIT with HDMA treatment in 11 years
old boy with recurrent severe AD from which he had suf-
fered for several years. After first 6 months of the treatment
the significant clinical improvement of his dermatitis was
noticed as well as the reduction of SCORAD to 15 and fur-
ther mild improvement after 12 months (SCORAD 12).
The condition of the affected skin which was resistant to
traditional therapy improved significantly. The child contin-
ued SLIT treatment with excellent tolerance to HDMA.
Based on that data the authors make a conclusion that
SLIT with long-term use can be a safe alternative treatment
of recurrent allergic AD.
The safety profile and efficacy of SLIT in children with
mild and moderate HDMA-induced AD, pointed out
that SLIT can be considered as a real option of treat-
ment of patients with ADs including AD [19, 43, 61, 62,
64–66, 68, 70]. By 2014 the evidences of SLIT efficacy in
treatment of different AD were already based on the
results of 77 clinical studies and 7 meta-analyses [62].
AIT for AD the optimism and the issues
Despite the fact that there is a great progress in intro-
duction of AIT there are still a lot of questions that re-
main unanswered [24, 48]. One of them is the use of
AIT in AD especially in children that causes wide dis-
cussions in the scientific circles [48].
Usually AIT in children with AD is not used as a first
line therapy, so for infants and babies with positive fam-
ily anamnesis of AD, AIT should be considered as an
option for the secondary prevention from atopic diseases
[17]. If children have AD on the background of AR or
BA with sensitization to aeroallergens, AIT can be
considered as a therapeutic agent to reduce the progres-
sion of concomitant respiratory pathology as well as to
prevent the sensitization to unrelated allergens (SCIT
-[25, 38, 74, 92]; SLIT – [36, 51, 52]).
The clinical efficacy of AIT for patients with AD, espe-
cially for children, is controversial. The amount of studies
Slavyanakaya et al. World Allergy Organization Journal  (2016) 9:15 Page 7 of 11in this area for adults using various variants of AIT in AD
significantly exceeds the ones conducted for children, and
question of possibility of extrapolation of adult data to
children’s ones remains open, though similar pathogenic
mechanisms of development of allergic inflammation lay
on the basis of development of Ig-E-mediated ADs. How-
ever, the strength of immune response may vary and
depends on individual characteristics of a child.
Conducted all over the world for the past 30 years
numerous both open, pilot and double, blind, placebo-
controlled studies, review of systematic and meta-analyses,
have allowed to identify the conditions under which AIT
may be useful in AD. At the moment it can be stated that
AIT, in compliance with all necessary conditions for its
implementation, can be really effective and safe treatment
option for a specific group of patients with IgE-mediated
AD with sensitization to aeroallergens (in particular, to
HDMA, grass and plants pollen allergens) or in severe
uncontrolled form of AD when the benefits of using AIT
exceed the risk of adverse effects occurrence.
In Table 3 shows the comparative clinical effectiveness of
SCIT vs SLIT in AD, where the evidences that have already
been confirmed in clinical trials are listed. Also, there are
the questions mentioned that still remain unanswered.
For the AIT conduction there should be a strict selection
of patients with prior research in the area to confirm the
diagnosis of IgE-mediated disease. The preliminary diag-
nostics of immunopathogenetic phenotype of AD and
pathophysiological disorders, including immune, will allow
a doctor to develop the appropriate algorithm of complex
treatment of AD in children, aimed at their correction.
The individual approach is required to adjust allergen dose
for AIT taking into account pathophysiological and im-
mune changes, the degree of patient’s allergization, defined
by skin tests, which can be further also used to assess the
clinical efficacy of AIT in children in the treatment process.
A very important factor is setting an age limit to start the
immunotherapy (often AIT is recommended to start treat-
ing in children of minimum 5 years old). The use of AIT
must be justified and conducted under a highly qualified
doctor’s supervision, regardless of the ways of infusion the
allergens.
Nowadays there is a lot of documents regulating the
conduct of AIT in patients with respiratory allergy, in-
cluding children, however there are still no clear recom-
mendations regarding AD. All guidelines mark AD as a
disease that requires further careful research. The unmet
needs of AIT treatment in children with AD coincide in
many ways with those for children with AR and BA,
which were published by EAACI in 2012 [17]. In AD,
however, there is no clearly defined methodological base
where all the guiding principles of AIT conduct could be
registered, where could be taken into account the optimal
doses and schemes, safety of methods and possibleadverse effects, the rules of first aid, indications and con-
traindications, impact on life quality, pharmaco-economic
aspects, etc.
Recently published randomized results of the com-
bined use of the two methods (SCIT and SLIT) in chil-
dren for the treatment of BA and AR [60] have shown
the best clinical efficacy compared to the use of mono
method (separately SCIT or SLIT) or BT. The new inter-
pretation of AIT method has proved to be the most
promising, as it has included the abilities of both im-
munotherapy methods: SCIT has quickly activated the
tolerogenic to cause-significant allergens at the initial
stage of treatment, and SLIT later has provided the
safety in long-term use. From our point of view, this
method can be interesting when conducting AIT in chil-
dren with AD, but for sure it is necessary to carry out
the randomized studies to confirm its efficacy.
Conclusion
The important advantages of AIT are: specific allergens
and patients can be identified by suitable diagnostics; it
is disease-modifying; it has long-lasting effect even after
discontinuation; is more effective than pharmacotherapy.
However, therapeutic utilization remains at low level due
to poor compliance; inconvenient dosing; therapy with
wild type allergen prone to have side effects.
The literature contains very limited evidence regarding
the use of AIT in AD in children that dictates the need
for additional large-scale randomized clinical trials with
modern allergen and standardized protocols, the results
of which will not only help to identify short-term and
long-term protection from AD, but also to develop the
guidelines and position papers regulating the use of AIT
in children considering their peculiarities.
Most of the researches using AIT in AD in children
are usually conducted in open uncontrolled trials or rep-
resent a series of reports on individual cases. These
studies are difficult to compare, because there have been
used the allergens from different pharmaceutical com-
panies, doses and schemes of which, in this connection,
are difficult to compare.
Using SLIT in AD is under study and more evidences
are needed to support its clinical use, especially using
SLIT in HDM allergens. Considering the excellent safety
profile, the ability to influence on allergic inflammation,
SLIT has huge potential to become a candidate for
pathogenetic treatment of AD.
AIT, according to experts [12, 17, 19], has the follow-
ing main unmet needs:
 Insufficient safety and efficacy;
 Insufficient profile of risk/benefit
 The lack of biomarkers to predict the course of the
disease
Table 3 Comparative effectiveness of different methods of AIT in AD in children (SLIT vs SCIT)
CLINICAL
EFFICACY
AIT (route of administration)
SCIT SLIT
WHAT IS
KNOWN?
(+) in Ig-E mediated AD (+) in Ig-E mediated AD
(+) in AD in combination with respiratory allergies (AR and BA) (+) in AD in combination with respiratory allergies (AR and BA)
(+) to mono aeroallergens (HDM, pollen of grass and plants) (+) to mono aeroallergens (HDM, pollen of grass and plants)
(+) to a mixture of aeroallergens (HDM, pollen of grass and
plants)
(−)
Have been identified effective and ineffective doses for many
allergens
Have been identified the appropriate dosages for SLIT tablets for
aeroallergens (allergens of grass, ragweed and house dust mites)
Possibly greater efficacy (at least first year) (−)
Effective when using a mixture of multiple aeroallergens (−) to a mixture of aeroallergens (HDM, pollen of grass and plants)
The main duration of therapy is 3–5 years The optimal duration of therapy is 3-4 years
Prevention of new sensitization and progression of respiratory
allergies (AR and allergic BA)
Prevention of new sensitization and progression of allergic BA
Lasting effect after termination of treatment Lasting effect after termination of treatment
May cause local and systemic reactions Improved safety compared to SCIT (mostly, temporary local reactions)
More systemic reactions
Inconvenient in use (requires special conditions: a trained
expert, equipped rooms and conducting in outpatient
conditions, patient’s observation)
More convenient in use compared to SCIT (can be applied at home)
WHAT REMAINS
UNANSWERED?
The comparative efficacy compared to SLIT The comparative efficacy compared to SCIT. Possibly less effective
(at least first year)
Possibly more effective (at least first year)
Optimal dosing of SLIT in drops Optimal dosing regimens are
defined only for grass, ragweed and HDM tablets
The possibility of using mixtures of multiple unrelated allergens
Multiple allergen mixes can be less effective.
Note: AIT allergen specific immunotherapy, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, AD atopic dermatitis, AR allergic rhinitis, BA
allergic bronchial asthma, HDM house-dust mite, (+) clinical efficacy, (−) clinically ineffective or poorly understood
Slavyanakaya et al. World Allergy Organization Journal  (2016) 9:15 Page 8 of 11 Optimal protocols (dose and frequency of
administration)
 The Lack of general standard doses of allergens
(aeroallergens in particular) in extracts for AIT
(standardized extracts)
 Local and systemic reactions
 The Frequency of adverse effects and safety
 The definition of the duration and severity of the
disease before treatment
 The minimum age of children for conducting AIT
 Difficulty in conducting large-scale, double-blind
placebo-controlled, blind, randomized clinical trials
in children
 Criteria for children selection to participate in
randomized trials
 The efficacy and safety of AIT in patients not
responding to pharmacotherapy
 Adherence to treatment
 The criteria for selection of patients for AIT
 The AIT optimization (the combined use of SCIT
and SLIT and optimal terms for its conduction)
 Pharmaco-economic aspects (the high cost of AIT)
 Legal and ethical issuesImprovements of current AIT required in four
main aspects:
 Efficacy: suppression of symptoms early and
sustained
 Manufacturability: low cost and reproducible
During the manufacture of house dust mite extracts
for diagnosis and immunotherapy in patients with AD
it’s necessary to ensure the presence of all important
mite allergens in the extracts. An improvement of the
situation can only be expected from the use of defined
recombinant allergens [15].
 Patient Convenience: fewer dose applications
 Safety: no anaphylaxis potential and no late phase
reactions
However, the latest fundamental achievements in Im-
munology and Allergology have made a rapid break-
through in the field of discovering the basic mechanisms
of AIT and studying the major immune and not immune
mechanisms of AD development, which are able not
Slavyanakaya et al. World Allergy Organization Journal  (2016) 9:15 Page 9 of 11only to initiate the disease, but also affect on its duration
and severity [34, 35, 42, 43, 49, 57, 83, 87].
In this regard the new strategies of AD treatment
should include a comprehensive immunotherapy includ-
ing the use of AIT and other biologically active agents
able to interfere with pathophysiological processes [1–6,
44]. Use of the successes of modern molecular allergol-
ogy, in particular, Molecular-based allergy diagnostics
(Allergen Chip technology) will help to optimize and
personalize the process of selecting the necessary aller-
gens to determine the most appropriate vaccines for
children considering the results of the allergen component
diagnostics. Microchip diagnostics in pediatric Allergy is
very important for conducting AIT: risk assessment and
prognosis, improvement of the accuracy of diagnosis and
cross-reactive sensitization in poly-sensitized patients,
thereby improving the understanding of triggering aller-
gens; identifying patients and triggering allergens for AIT
[18]. Microarray diagnostics in pediatric allergy is the per-
fect tool for the diagnosis of IgE sensitization and allergic
diseases in children.
The joint efforts of scientists and clinicians will cer-
tainly bring the benefits and will help the patients with
AD to cope with their disease.
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